CSP Mylan Ireland Limited Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: CSP Mylan Ireland Limited Pharmaceutical Import Records from India — 3 Products, $657.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

CSP Mylan Ireland Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $657.6K Trade | TransData Nexus

CSP Mylan Ireland Limited

Pharmaceutical Importer · France · Oncology Focus · $657.6K Total Trade · DGFT Verified

CSP Mylan Ireland Limited is a pharmaceutical importer based in France with a total trade value of $657.6K across 3 products in 2 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. CSP Mylan Ireland Limited sources from 1 verified Indian supplier, with Mylan Laboratories Limited accounting for 100.0% of imports.

CSP Mylan Ireland Limited — Import Portfolio & Supplier Network

CSP Mylan Ireland Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to CSP Mylan Ireland Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$219.7K	5	100.0%

CSP Mylan Ireland Limited sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Mylan Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Epirubicine viatris 200MG/100ML 1 france(7802486) tax val	$50.0K	1
Etoposide viatris 200MG/10ML 10s france( 7802497) tax val	$50.0K	1
Etoposide viatris 200MG/10ML 10s france( 7802500) tax val	$50.0K	1
Cisplatin viatris 1MG-100ML 1 via france( 7802503) tax val	$45.8K	1
Methotrexate viatris 50MG/2ML 10s france7802384 tax val	$23.9K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cisplatin	Oncology	$457.6K	10	3.6%	3
2	Epirubicin	Advanced Oncology	$100.0K	2	1.6%	9
3	Etoposide	Oncology	$100.0K	2	0.9%	8

CSP Mylan Ireland Limited imports 3 pharmaceutical products across 2 categories into France totaling $657.6K.

CSP Mylan Ireland Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

CSP Mylan Ireland Limited is a pharmaceutical importer and buyer based in France, specializing in the acquisition of finished pharmaceutical formulations. The company operates as a subsidiary of Mylan Laboratories Limited, a global leader in the production and distribution of generic and specialty medicines. Mylan Laboratories Limited, headquartered in Dublin, Ireland, has a significant presence in the European pharmaceutical market, including France. CSP Mylan Ireland Limited plays a pivotal role in facilitating the importation and distribution of Mylan's pharmaceutical products within France, ensuring a steady supply of essential medications to meet the needs of the French healthcare system.

2Distribution Network

CSP Mylan Ireland Limited's distribution network in France is strategically designed to ensure efficient delivery of pharmaceutical products across the country. The company operates multiple warehouses located in key regions, enabling prompt and reliable distribution to various healthcare providers, including hospitals, pharmacies, and clinics. Leveraging advanced logistics capabilities, CSP Mylan Ireland Limited maintains a robust supply chain that ensures timely replenishment of stock, thereby supporting the continuous availability of critical medications throughout France.

3Industry Role

Within France's pharmaceutical supply chain, CSP Mylan Ireland Limited functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Mylan Laboratories Limited in Ireland, the company ensures the availability of a diverse range of medications in the French market. This role is crucial in maintaining the supply of essential drugs, particularly in therapeutic areas such as oncology, where specialized treatments are in high demand.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — CSP Mylan Ireland Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CSP Mylan Ireland Limited's sourcing strategy exhibits a high degree of concentration, with all 14 shipments from India originating from a single supplier, Mylan Laboratories Limited. This single-source dependency may present risks, such as potential supply chain disruptions due to unforeseen events affecting the supplier. However, the consistent volume of imports and the established relationship between CSP Mylan Ireland Limited and Mylan Laboratories Limited suggest a stable and reliable supply chain. The strategic choice to source exclusively from Mylan Laboratories Limited likely aims to ensure product quality and regulatory compliance, given the supplier's established reputation in the pharmaceutical industry.

2Supply Chain Resilience

The resilience of CSP Mylan Ireland Limited's supply chain is closely tied to the stability and reliability of Mylan Laboratories Limited. The company's exclusive sourcing from this single supplier indicates a deep integration and trust in Mylan Laboratories Limited's manufacturing and distribution capabilities. While this approach streamlines operations and ensures consistency in product quality, it also means that CSP Mylan Ireland Limited's supply chain is vulnerable to any disruptions affecting Mylan Laboratories Limited. To enhance resilience, CSP Mylan Ireland Limited may consider diversifying its supplier base or establishing contingency plans to mitigate potential risks.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the Agence nationale de sécurité du médicament et des produits de santé (ANSM). The ANSM is responsible for ensuring the safety, efficacy, and quality of medicinal products available in the French market. Key legislation governing pharmaceutical imports includes the French Public Health Code, which outlines the requirements for manufacturing, importing, and distributing medicinal products. For Indian generics to be marketed in France, they must undergo a marketing authorization process, which involves demonstrating compliance with the standards set by the ANSM. This process ensures that imported generics meet the necessary criteria for safety and efficacy before they are made available to patients.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France are stringent, necessitating that all imported medicinal products possess a valid marketing authorization issued by the ANSM. Additionally, the French Public Health Code mandates that manufacturers and importers comply with Good Manufacturing Practice (GMP) standards. For Indian exporters, recognition of their GMP certificates by the European Medicines Agency (EMA) or the World Health Organization (WHO) is essential for facilitating the importation of their products into France. Furthermore, wholesale distribution authorization is required for entities involved in the distribution of medicinal products within France, ensuring that all intermediaries in the supply chain adhere to regulatory standards.

CSP Mylan Ireland Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CSP Mylan Ireland Limited's product strategy focuses on importing finished pharmaceutical formulations in the oncology therapeutic area, with a particular emphasis on advanced oncology treatments. This focus aligns with the growing demand for specialized cancer therapies in France, driven by an aging population and advancements in cancer research. By concentrating on these specific therapeutic areas, CSP Mylan Ireland Limited aims to address critical unmet medical needs and provide healthcare professionals with effective treatment options for their patients.

2Sourcing Profile

CSP Mylan Ireland Limited's sourcing strategy is centered on acquiring generic drugs from Mylan Laboratories Limited, ensuring access to a broad portfolio of high-quality, cost-effective medications. The company's preference for finished pharmaceutical formulations over active pharmaceutical ingredients (APIs) reflects a strategic decision to streamline operations and maintain control over the final product quality. India's role as a major supplier of generics aligns with CSP Mylan Ireland Limited's procurement objectives, leveraging India's manufacturing capabilities and regulatory compliance to meet the demands of the French market.

3Market Positioning

Seller's Guide — How to Become a Supplier to CSP Mylan Ireland Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with CSP Mylan Ireland Limited, particularly in the oncology therapeutic area. The company's exclusive sourcing from Mylan Laboratories Limited indicates a potential openness to diversifying its supplier base, provided that new suppliers can meet the stringent regulatory and quality standards required by the French market. Gaps in CSP Mylan Ireland Limited's current sourcing may include specific formulations or dosages not currently available, presenting opportunities for Indian exporters to introduce complementary products that align with the company's therapeutic focus.

2Requirements & Qualifications

Indian exporters seeking to supply CSP Mylan Ireland Limited and the French market must obtain marketing authorization from the ANSM, demonstrating compliance with French regulatory standards. Additionally, GMP certificates recognized by the EMA or WHO are essential to ensure that manufacturing processes meet international quality standards. Products must undergo batch testing and stability studies, with labeling provided in French to meet regulatory requirements. Serialization of products is mandatory to enhance traceability and prevent counterfeit medicines from entering the supply chain.

Frequently Asked Questions — CSP Mylan Ireland Limited

What products does CSP Mylan Ireland Limited import from India?

CSP Mylan Ireland Limited imports 3 pharmaceutical products across 2 categories. Top imports: Cisplatin ($457.6K), Epirubicin ($100.0K), Etoposide ($100.0K).

Who supplies pharmaceuticals to CSP Mylan Ireland Limited from India?

CSP Mylan Ireland Limited sources from 1 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (100.0% of imports, $219.7K).

What is CSP Mylan Ireland Limited's total pharmaceutical import value?

CSP Mylan Ireland Limited's total pharmaceutical import value from India is $657.6K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does CSP Mylan Ireland Limited focus on?

CSP Mylan Ireland Limited imports across 2 categories. The largest: Oncology (84.8%), Advanced Oncology (15.2%).

Get Full CSP Mylan Ireland Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

CSP Mylan Ireland Limited

CSP Mylan Ireland Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to CSP Mylan Ireland Limited?

What Formulations Does CSP Mylan Ireland Limited Import?

What Products Does CSP Mylan Ireland Limited Import?

Top Products by Import Value

CSP Mylan Ireland Limited Therapeutic Categories — 2 Specializations